← Back to Search

LDCT Lung Screening for Early Detection of Lung Cancer

N/A
Recruiting
Led By Daniel Carrizosa, MD
Research Sponsored by Daniel Carrizosa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 40-54 years at the time of consent.
Ability to read and understand the English and/or Spanish language.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights

Study Summary

This trial is testing whether lowering the minimum age for low-dose CT screening from 55 to 50 will decrease mortality in a high-risk population.

Who is the study for?
This trial is for people aged 40-54 who have a significant smoking history (at least 30 pack years), are currently smoking or quit within the last 15 years, and can understand English/Spanish. They must consent to share health information and follow study procedures. Those with past lung cancer diagnosis, CT scan contraindications, or pregnancy cannot join.Check my eligibility
What is being tested?
The study tests if lowering the age for Low-dose Computed Tomography (LDCT) screening can help detect lung cancer earlier in smokers or recent quitters aged 40-54. This follows evidence that LDCT improves survival rates in older individuals.See study design
What are the potential side effects?
While LDCT itself has minimal side effects, potential risks include exposure to low levels of radiation which may slightly increase the risk of developing cancer over one's lifetime.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 40 and 54 years old.
Select...
I can read and understand either English or Spanish.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Lung cancer diagnosis rate in individuals 40-54 years of age at their first screening (T0) with mobile low-dose CT.
Secondary outcome measures
Impact of baseline demographic (including insurance status), socioeconomic, and healthcare-related factors on lung cancer rates and positive screening rates
Incidence rate of all types of cancer found with low-dose lung CT during lung cancer screening
Lung cancer diagnosis rate in individuals 40-54 years of age at subsequent screening visits (T1 and T2)
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
Mobile Low-dose Computed Tomography (LDCT) Screening

Find a Location

Who is running the clinical trial?

Daniel CarrizosaLead Sponsor
Leon Levine FoundationUNKNOWN
Wake Forest University Health SciencesLead Sponsor
1,253 Previous Clinical Trials
1,009,772 Total Patients Enrolled

Media Library

Mobile Low-dose Computed Tomography (LDCT) Screening Clinical Trial Eligibility Overview. Trial Name: NCT04577599 — N/A
Lung Cancer Research Study Groups: Single Arm
Lung Cancer Clinical Trial 2023: Mobile Low-dose Computed Tomography (LDCT) Screening Highlights & Side Effects. Trial Name: NCT04577599 — N/A
Mobile Low-dose Computed Tomography (LDCT) Screening 2023 Treatment Timeline for Medical Study. Trial Name: NCT04577599 — N/A
~326 spots leftby Oct 2025